Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF)
- PMID: 2676851
- DOI: 10.1016/s0171-2985(89)80012-9
Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF)
Abstract
Specific T cell factors, such as specific macrophage arming factor (SMAF), are involved in the initiation of the immune response. Induction of SMAF-producing T lymphocytes in vivo and of SMAF production by T lymphocytes in vitro is dependent on the presence of intact tumor cells, and is independent of antigen presentation by macrophages. SMAF renders peritoneal macrophages cytotoxic for tumor cells. The armed peritoneal macrophages expressed a specific cytotoxicity. However, antigen-presenting cells can trigger lymphokine-producing T lymphocytes. These T lymphocytes produce lymphokines (e.g. macrophage activating factor (MAF] that activate macrophages. The MAF-activated macrophages express a non-specific tumoricidal activity. In the present study, we investigated the difference in the induction of macrophage cytotoxicity by SMAF and MAF. The following differences were found: 1) SMAF renders peritoneal resident macrophages cytotoxic, whereas MAF could only render peritoneal exudate macrophages cytotoxic. 2) SMAF requires only a 4-h incubation with macrophages, whereas MAF activates macrophages optimally after 12 h. 3) SMAF-armed macrophages recognize only the specific target cell(s), and thus, the cytotoxicity is specific in its expression. MAF activated macrophages were non-specifically cytotoxic. 4) Lipopolysaccharide (LPS) in the culture medium did not enhance the cytotoxicity of SMAF-armed macrophages. In contrast, MAF induced tumoricidal activity was enhanced by adding LPS to the culture medium. 5) After adsorption chromatography with anti-murine interferon-gamma (IFN-gamma), the arming capacity of SMAF supernatant was not reduced, whereas the activating capacity of the MAF supernatant was significantly reduced or abrogated. After immunization of mice with allogeneic tumor cells, SMAF-producing lymphocytes were detected in the draining lymph nodes already 4 days after immunization and up to 12 days. Lymphocytes with the capacity to produce MAF were present in the draining lymph nodes 14-24 days after immunization. Our data indicate that the T cell factors SMAF and MAF can both render macrophages cytotoxic, but act in a different way and during different stages of the cellular immune response against allogeneic tumor cells.
Similar articles
-
Lymphocyte-induced macrophage cytotoxicity. III. Induction of specific macrophage cytotoxicity is independent of lipopolysaccharide.Immunobiology. 1986 Apr;171(3):170-9. doi: 10.1016/s0171-2985(86)80002-x. Immunobiology. 1986. PMID: 3486815
-
Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.J Immunol. 1985 Sep;135(3):2199-205. J Immunol. 1985. PMID: 3894520
-
The induction of lymphocytes with the capacity to render macrophages cytotoxic in an allogeneic murine system.Immunology. 1982 Nov;47(3):541-50. Immunology. 1982. PMID: 6215342 Free PMC article.
-
Identification of gamma-interferon as a murine macrophage-activating factor for tumor cytotoxicity.Contemp Top Immunobiol. 1984;13:171-98. doi: 10.1007/978-1-4757-1445-6_9. Contemp Top Immunobiol. 1984. PMID: 6428805 Review. No abstract available.
-
Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.Cancer Metastasis Rev. 1988 Dec;7(4):289-309. doi: 10.1007/BF00051371. Cancer Metastasis Rev. 1988. PMID: 2974763 Review.
Cited by
-
M1 macrophages - unexpected contribution to tumor progression.Front Immunol. 2025 Jul 31;16:1638102. doi: 10.3389/fimmu.2025.1638102. eCollection 2025. Front Immunol. 2025. PMID: 40821768 Free PMC article. Review.
-
Initial immunochemical characterization of specific macrophage-arming factor.Cancer Immunol Immunother. 1989;30(1):21-7. doi: 10.1007/BF01665026. Cancer Immunol Immunother. 1989. PMID: 2598172 Free PMC article.
-
Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.Cancer Immunol Immunother. 1989;30(1):28-33. doi: 10.1007/BF01665027. Cancer Immunol Immunother. 1989. PMID: 2598173 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources